These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34182131)

  • 41. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective and nonselective inhibition of thromboxane formation.
    FitzGerald GA; Oates JA
    Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
    Norris LA; Devitt M; Bonnar J
    Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
    FitzGerald GA; Oates JA; Hawiger J; Maas RL; Roberts LJ; Lawson JA; Brash AR
    J Clin Invest; 1983 Mar; 71(3):676-88. PubMed ID: 6338043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation.
    Modesti PA; Colella A; Cecioni I; Costoli A; Biagini D; Migliorini A; Neri Serneri GG
    Am Heart J; 1995 May; 129(5):873-9. PubMed ID: 7732975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man.
    Böger RH; Bode-Böger SM; Gutzki FM; Tsikas D; Weskott HP; Frölich JC
    Clin Sci (Lond); 1993 May; 84(5):517-24. PubMed ID: 8504628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.
    Preston FE; Whipps S; Jackson CA; French AJ; Wyld PJ; Stoddard CJ
    N Engl J Med; 1981 Jan; 304(2):76-9. PubMed ID: 7003384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelets Promote Ang II (Angiotensin II)-Induced Atrial Fibrillation by Releasing TGF-β1 (Transforming Growth Factor-β1) and Interacting With Fibroblasts.
    Liu Y; Lv H; Tan R; An X; Niu XH; Liu YJ; Yang X; Yin X; Xia YL
    Hypertension; 2020 Dec; 76(6):1856-1867. PubMed ID: 33175633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiplatelet therapy: targeting the TxA2 pathway.
    Fontana P; Zufferey A; Daali Y; Reny JL
    J Cardiovasc Transl Res; 2014 Feb; 7(1):29-38. PubMed ID: 24353037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
    Bode-Böger SM; Böger RH; Schubert M; Frölich JC
    Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis.
    Weksler BB; Tack-Goldman K; Subramanian VA; Gay WA
    Circulation; 1985 Feb; 71(2):332-40. PubMed ID: 3880671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
    DeFilippis AP; Oloyede OS; Andrikopoulou E; Saenger AK; Palachuvattil JM; Fasoro YA; Guallar E; Blumenthal RS; Kickler TS; Jaffe AS; Gerstenblith G; Schulman SP; Rade JJ
    Circ J; 2013; 77(11):2786-92. PubMed ID: 23985963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
    Shankar H; Garcia A; Prabhakar J; Kim S; Kunapuli SP
    J Thromb Haemost; 2006 Mar; 4(3):638-47. PubMed ID: 16460446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
    Kobayashi T; Tahara Y; Matsumoto M; Iguchi M; Sano H; Murayama T; Arai H; Oida H; Yurugi-Kobayashi T; Yamashita JK; Katagiri H; Majima M; Yokode M; Kita T; Narumiya S
    J Clin Invest; 2004 Sep; 114(6):784-94. PubMed ID: 15372102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium.
    Packham MA; Kinlough-Rathbone RL; Mustard JF
    Blood; 1987 Sep; 70(3):647-51. PubMed ID: 3620698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostacyclin and thromboxane A2 release in isolated rat lungs.
    Korbut R; Boyd J; Eling T
    Prostaglandins; 1982 Jan; 23(1):67-75. PubMed ID: 7038777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic Depletion of Thromboxane A2/Thromboxane-Prostanoid Receptor Signalling Prevents Microvascular Dysfunction in Ischaemia/Reperfusion Injury.
    Chiang CY; Chien CY; Qiou WY; Chang C; Yu IS; Chang PY; Chien CT
    Thromb Haemost; 2018 Nov; 118(11):1982-1996. PubMed ID: 30300909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.